Targeted drug raises new hope for cervical cancer patients
Targeted drug raises new hope for cervical cancer patients
- There’s good news for patients suffering from cervical cancer, the second most common cancer in women. In a clinical study, scientists have discovered that a drug erlotinib, a targeted anti-tumour agent, has potential to improve treatment for cervical cancer when combined with chemoradiation therapy. The new treatment strategy involves targeting the epithelial growth factor receptor (EGFR), which is frequently over-expressed in cervical cancer.
- There’s good news for patients suffering from cervical cancer, the second most common cancer in women. In a clinical study, scientists have discovered that a drug erlotinib, a targeted anti-tumour agent, has potential to improve treatment for cervical cancer when combined with chemoradiation therapy. The new treatment strategy involves targeting the epithelial growth factor receptor (EGFR), which is frequently over-expressed in cervical cancer.